← Back to Clinical Trials
Recruiting NCT02615600

NCT02615600 Daily Bitemporal Low-frequency Transcranial Random Noise Stimulation in Tinnitus (tRNS2-tin)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02615600
Status Recruiting
Phase
Sponsor University of Regensburg
Condition Chronic Tinnitus
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2015-11
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
lf-tRNS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2015-11 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Stimulation of the left and right auditory cortex with daily low-frequency transcranial random noise stimulation (tRNS) is used to modulate the neural pathways involved in chronic tinnitus.

Eligibility Criteria

Inclusion criteria: * diagnosis of bothersome, subjective chronic tinnitus * diagnosis: duration of tinnitus more than 6 months Exclusion criteria: * objective tinnitus * irregular head shap below the electrodes * eczema on the head * treatable cause of the tinnitus * involvement in other treatments for tinnitus at the same time * clinically relevant psychiatric comorbidity * clinically relevant unstable internal or neurological comorbidity * history of or evidence of significant brain malformation or neoplasm, head injury * cerebral vascular events * neurodegenerative disorder affecting the brain or prior brain surgery * metal objects in and around body that can not be removed * pregnancy * alcohol or drug abuse

Contact & Investigator

Central Contact

Berthold Langguth

✉ berthold.langguth@medbo.de
Principal Investigator

Berthold Langguth

PRINCIPAL INVESTIGATOR

University of Regensburg

Frequently Asked Questions

Who can join the NCT02615600 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Chronic Tinnitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02615600 currently recruiting?

Yes, NCT02615600 is actively recruiting participants. Contact the research team at berthold.langguth@medbo.de for enrollment information.

Where is the NCT02615600 trial being conducted?

This trial is being conducted at Regensburg, Germany.

Who is sponsoring the NCT02615600 clinical trial?

NCT02615600 is sponsored by University of Regensburg. The principal investigator is Berthold Langguth at University of Regensburg. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology